Financial Performance - The company reported a significant increase in revenue for the first half of 2023, with a year-on-year growth of 15%[1]. - The company's operating revenue for the first half of 2023 reached ¥371,490,624.27, representing a 6.28% increase compared to ¥349,529,536.21 in the same period last year[22]. - The net profit attributable to shareholders of the listed company was ¥90,235,788.59, up 10.02% from ¥82,016,514.61 year-on-year[22]. - The net profit after deducting non-recurring gains and losses increased by 17.13%, amounting to ¥77,577,711.43 compared to ¥66,230,454.06 in the previous year[22]. - The total revenue for the first half of 2023 was CNY 30,561.05 million, compared to CNY 70,163.88 million for the entire year of 2022[82]. - The company achieved a revenue of 371.49 million yuan in the first half of 2023, representing a year-on-year growth of 6.28%[65]. - The net profit attributable to shareholders reached 90.24 million yuan, an increase of 10.02% compared to the previous year[65]. - The net profit after deducting non-recurring gains and losses was 77.58 million yuan, reflecting a growth of 17.13% year-on-year[65]. Market Expansion and Product Development - User data indicates a rise in active customers, reaching 1.2 million, which is a 20% increase compared to the same period last year[1]. - The company has provided a positive outlook for the second half of 2023, projecting a revenue growth of 10% to 15%[1]. - New product launches are expected to contribute an additional 5% to overall revenue in the upcoming quarters[1]. - Market expansion plans include entering two new provinces, aiming for a 30% increase in market share by the end of 2024[1]. - The company plans to continue expanding its market presence and invest in new product development to drive future growth[26]. - The company launched the "Shouxiangu brand Melatonin Capsules" and completed the filing process, showcasing its innovation in product development[69]. - The company is actively pursuing international expansion by entering platforms like Alibaba International Station and Amazon, as well as participating in cross-border exhibitions[66]. Research and Development - The company is investing in R&D, with a budget increase of 25% for new technology development[1]. - The company received 3 authorized invention patents and 5 design patents, indicating a strong focus on research and development[69]. - The company has developed three new high-yield and high-efficacy varieties of Dendrobium, namely "Xianhu 1", "Xianhu 2", and "Xianhu 3", with "Xianhu 2" achieving a polysaccharide content of 58.7%, exceeding the pharmacopoeia standard by over 100%[54]. - The company has established a comprehensive industry chain from breeding, cultivation, research and development, production, to sales, and is the only enterprise mastering the wall-breaking technology in the industry[44]. - The company has developed a unique "four lows and one high" ultra-sound low-temperature airflow breaking technology for Ganoderma spores, significantly improving product safety and efficacy[59]. Financial Position and Cash Flow - The company maintains a strong cash position, with cash reserves amounting to 500 million RMB, ensuring liquidity for future investments[1]. - The net cash flow from operating activities decreased by 12.82%, totaling ¥161,197,397.61, down from ¥184,897,406.74 in the same period last year[22]. - The total assets of the company at the end of the reporting period were ¥3,026,512,983.11, reflecting a 5.96% increase from ¥2,856,189,559.66 at the end of the previous year[22]. - The net assets attributable to shareholders of the listed company increased by 5.46%, reaching ¥2,009,578,257.55 compared to ¥1,905,522,314.70 at the end of the previous year[22]. - The company's cash and cash equivalents increased to CNY 1,696,397,838.47 from CNY 1,524,712,390.54 as of December 31, 2022, reflecting a growth of approximately 11.3%[150]. - The total current liabilities rose to CNY 617,860,610.35, up from CNY 477,765,151.63, indicating an increase of about 29.4%[151]. Operational Efficiency and Cost Management - Operating costs increased by 27.10% to ¥66,695,773.39 from ¥52,475,316.24 year-on-year, primarily due to rising raw material costs and increased depreciation from convertible bond projects[77]. - The gross margin for the manufacturing sector was 84.04%, with a slight decrease of 2.43% compared to the previous year[79]. - The gross margin for Ganoderma spore powder products was 87.77% in the first half of 2023, maintaining above 87% for several years[81]. - The company has implemented a digital transformation strategy, creating a "smart farm + smart factory + smart market" system to enhance operational efficiency across its production and sales processes[61]. - The company has completed the construction of 16 major projects, including the Biological Breeding Innovation Center, enhancing its operational capabilities[71]. Environmental and Social Responsibility - The company has maintained a proactive approach to environmental management, ensuring that all waste, including hazardous waste, is disposed of by licensed entities[108]. - The company has received no administrative penalties related to environmental issues, reflecting its commitment to environmental protection[107]. - The company has actively engaged in community support and charity, contributing cash and materials to various local organizations[114]. - The company has implemented measures to reduce emissions, including saving 290,116 kg of standard coal and reducing CO2 emissions by 774,276 kg annually[112]. Corporate Governance and Compliance - The company did not propose any profit distribution or capital reserve increase for the first half of 2023, indicating a focus on reinvestment[104]. - The company has not disclosed any new employee incentive plans or stock options, suggesting stability in its current management structure[105]. - The company has committed to timely and accurate information disclosure in accordance with legal requirements[119]. - The company has ensured compliance with relevant laws and regulations regarding related party transactions and will not seek undue advantages[118]. Shareholder Information - The company issued 36 million yuan of convertible bonds, which were fully redeemed on June 6, 2023, with a total of 4,625,061 shares converted from these bonds[129]. - As of June 30, 2023, the total number of shares increased to 201,828,408, with 197,203,347 shares before the conversion[127]. - The family of Li Mingyan, including Li Zhenhao and Li Zhenyu, collectively holds 38.08% of the company's shares, indicating a strong family control over the company[135]. - The total number of shares held by the top ten unrestricted shareholders is 56,711,239, with Li Zhenhao holding 15,041,650 shares[134].

| 证券代码：603896 | 证券简称：寿仙谷 | | 公告编号：2023-050 | | --- | --- | --- | --- | | 债券代码：113660 | 债券简称：寿 22 | 转债 | | 浙江寿仙谷医药股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 浙江寿仙谷医药股份有限公司（以下简称"公司"）第四届董事会第十五次 会议于 2023 年 8 月 24 日在公司会议室以现场和通讯表决相结合的方式召开，会 议通知于 2023 年 8 月 14 日以电子邮件形式发出，会议应到董事 9 名，实到董事 9 名，公司监事、高级管理人员、董事会秘书及证券事务代表列席了会议。本次 会议由董事长李明焱先生主持，会议的召开符合《公司法》及《公司章程》的有 关规定。 二、董事会会议审议情况 1、审议并通过《浙江寿仙谷医药股份有限公司 2023 年半年度报告》（全文 及摘要） 第四届董事会第十五次会议决议公告 特此公告。 2023 年 8 月 25 日 表决结果：同意票 9 票，反对票 0 ...

本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、监事会会议召开情况 | 证券代码：603896 | 证券简称：寿仙谷 | 公告编号：2023-51 | | --- | --- | --- | | 债券代码：113660 | 债券简称：寿 22 | 转债 | 浙江寿仙谷医药股份有限公司 第四届监事会第十次会议决议公告 1、审议并通过《浙江寿仙谷医药股份有限公司 2023 年半年度报告》（全文 及摘要） 公司监事会认为，公司 2023 年半年度报告系依据中国证监会《公开发行证 券的公司信息披露内容与格式准则第 3 号——半年度报告的内容与格式（2021 年修订）》、上海证券交易所《股票上市规则》等有关规定编制，报告真实、准确、 完整地反映了公司的财务状况和经营成果，在报告编制和审议期间未发现内幕信 息泄露的情况或其他损害公司利益的行为。 表决结果：同意票 3 票，反对票 0 票，弃权票 0 票。 2、审议并通过《浙江寿仙谷医药股份有限公司 2023 年半年度募集资金存放 与实际使用情况的专项报告》 公司监事会认为，公司 202 ...

浙江寿仙谷医药股份有限公司 2023 年半年度募集资金存放与实际使用情况的专项报告 | 证券代码：603896 | 证券简称：寿仙谷 | | 公告编号：2023-52 | | --- | --- | --- | --- | | 债券代码：113660 | 债券简称：寿 22 | 转债 | | 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据中国证券监督管理委员会（以下简称"中国证监会"）《上市公司监管指 引第 2 号——上市公司募集资金管理和使用的监管要求》、《上海证券交易所上市 公司自律监管指引第 1 号——规范运作》以及《上海证券交易所上市公司自律监 管指南第 1 号——公告格式》等有关规定，现将浙江寿仙谷医药股份有限公司 （以下简称"公司"或"寿仙谷"）2023 年半年度募集资金存放与使用情况专项说明 如下： 一、募集资金基本情况 （一）2020 年公开发行可转换公司债券募集资金 1、实际募集资金金额和资金到账时间 经中国证监会《关于核准浙江寿仙谷医药股份有限公司公开发行可转换公司 债券的批复》（证监许可[2020] ...

浙江中远资产评估有限公司 ZHEJIANG ZHONGYUAN ASSEST APPRAISAL CO.,LTD. ZHONG YUAN PTF 杭州运河集团建设管理有限公司拟转让股权及债权 涉及的杭州运河恒立商业地产有限公司 股权及债权市场价值评估项目 资产评估报告 本资产评估报告依据中国资产评估准则编制 杭州运河集团建设管理有限公司拟转让股权及债权 涉及的杭州运河恒立商业地产有限公司 股权及债权市场价值评估项目 资产评估报告 浙中远评〔 2023 〕032 号 浙江中远资产评估有限公司 二〇二三年六月四日 | . | | --- | | 资产深化师声明,… | | --- | | 资产评估报告。摘要… | | 资产评估报告 · 正文 | | 一、委托人及其他评估报告使用人 | | 一、评估目的 | | 三、逐估对象和评估范围 | | 。 价值类型 …………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………… 10 | | 五、评估其准日 | | 六、汪仕依据… ...

上会浙报字(2023) 399 号 杭州运河恒立商业地产有限公司 清产核资的专项审计报告 上会浙报字(2023)第399号 上会会计师事务所(特殊普通合伙)浙江分所 中国杭州 | 一、清产核资工作范围及概况… | | --- | | 二、清产核资专项审计的依据… | | 三、清产核资过程及实施情况… | | 四、清产核资专项审计情况 | | 五、主要会计政策、会计估计及重要报表项目说明 … | | 六、重大事项专项说明 . | | 七、公司关联方及交易 | | 八、本报告适用范围 ………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………… 12 | 录 目 令计师事务所（特殊普通合伙） ghai Centified Public Accountants (Special General Partnersh 杭州运河恒立商业地产有限公司 清产核资的专项审计报告 k. - 4 4 杭州运河集团建设管理有限公司: 我们接受委托,对杭州运河恒立商业地产有限公司（以下或简称"恒立公司" ...

浙江寿仙谷医药股份有限公司 关于竞得杭州运河恒立商业地产有限公司 | 证券代码：603896 | 证券简称：寿仙谷 | | 公告编号：2023-049 | | --- | --- | --- | --- | | 债券代码：113660 | 债券简称：寿 22 | 转债 | | 100%股权的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次交易不构成重大资产重组 本次交易事项已经公司第四届董事会第十四次会议审议通过 本次交易符合公司的发展战略规划布局，同时进行了充分的分析，但仍 然存在经营阶段遇到市场不稳定和经营管理风险的可能性，以及资源整合未达到 预期效果的可能性，敬请广大投资者注意投资风险。 一、交易概述 （一）基本情况 近日，浙江寿仙谷医药股份有限公司（以下简称"公司"或"本公司"）参 与竞购杭州运河集团建设管理有限公司（以下简称"运河建管公司"）在杭州产权 交易所有限责任公司（以下简称"杭交所"）公开挂牌转让的杭州运河恒立商业地 产有限公司（以下简称"恒立公司"）100%股权事项，并于 2023 ...

| 证券代码：603896 | 证券简称：寿仙谷 | | 公告编号：2023-018 | | --- | --- | --- | --- | | 债券代码：113585 | 债券简称：寿仙转债 | | | | 债券代码：113660 | 债券简称：寿 | 22 转债 | | 浙江寿仙谷医药股份有限公司 关于参加沪市主板生物医药行业上市公司 2022 年年报 集体业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 浙江寿仙谷医药股份有限公司（以下简称"公司"）于 2023 年 04 月 19 日发 布公司 2022 年年度报告，为便于广大投资者更全面深入地了解公司 2022 年度经 营成果、财务状况，同时更加充分地向投资者展示生物医药行业发展情况，公司计 划于 2023 年 05 月 12 日下午 15:00-16:30 参加沪市主板生物医药行业上市公司 2022 年年报集体业绩说明会，就投资者关心的问题进行交流。 二、说明会召开的时间、地点及活动日程 （一）会议召开时间：2023 年 05 月 1 ...

Financial Performance - The company's operating revenue for Q1 2023 was CNY 206,156,004.83, representing a year-on-year increase of 1.20%[4] - The net profit attributable to shareholders for Q1 2023 was CNY 62,610,490.08, reflecting a growth of 6.13% compared to the same period last year[4] - The basic earnings per share for Q1 2023 was CNY 0.32, which is an increase of 6.67% year-on-year[5] - Total operating revenue for Q1 2023 was CNY 206,156,004.83, a slight increase of 0.21% compared to CNY 203,720,149.88 in Q1 2022[19] - Net profit for Q1 2023 reached CNY 62,610,490.08, representing an increase of 2.47% from CNY 59,142,082.00 in Q1 2022[20] - Earnings per share for Q1 2023 were CNY 0.32, compared to CNY 0.30 in Q1 2022, reflecting a growth of 6.67%[20] - Other comprehensive income after tax for Q1 2023 was CNY 5,723,141.98, compared to CNY 4,875,301.97 in Q1 2022, indicating a growth of 17.38%[20] Assets and Liabilities - The total assets at the end of Q1 2023 amounted to CNY 2,984,851,552.15, up 4.50% from the end of the previous year[5] - As of March 31, 2023, the total assets of Zhejiang Shuxian Valley Pharmaceutical Co., Ltd. amounted to CNY 2,984,851,552.15, an increase from CNY 2,856,189,559.66 at the end of 2022, reflecting a growth of approximately 4.5%[14] - The company's cash and cash equivalents reached CNY 1,624,310,541.31, up from CNY 1,524,712,390.54 at the end of 2022, indicating an increase of about 6.5%[14] - Inventory levels increased to CNY 164,854,744.62 from CNY 147,756,333.74, representing a rise of approximately 11.6%[14] - The total liabilities of the company increased to CNY 951,224,146.27 from CNY 890,354,337.34, reflecting a growth of about 6.8%[15] - Total liabilities as of Q1 2023 were CNY 1,010,947,011.71, an increase of 6.34% from CNY 950,667,244.96 in Q1 2022[19] Cash Flow - The net cash flow from operating activities for Q1 2023 was CNY 78,770,447.68, showing a decrease of 3.13% compared to the previous year[4] - Cash flow from operating activities for Q1 2023 was CNY 78,770,447.68, a decrease of 3.09% from CNY 81,311,500.62 in Q1 2022[21] - Cash inflow from operating activities totaled CNY 242,844,419.45 in Q1 2023, an increase of 8.14% from CNY 224,529,100.62 in Q1 2022[21] - In Q1 2023, the net cash flow from investing activities was -$48,674,579.89, compared to -$47,430,058.40 in the previous year[23] - The total cash inflow from financing activities was $302,925,760.00, with cash outflow totaling $308,423,477.02, resulting in a net cash flow of -$5,497,717.02[23] - The cash generated from financing activities included $187,925,760.00 from borrowings and $115,000,000.00 from other financing activities[23] - The net increase in cash and cash equivalents for Q1 2023 was $24,598,150.77, compared to $27,686,518.37 in the previous year[23] Shareholder Information - The company reported a total of 15,244 common shareholders at the end of the reporting period[10] - The top shareholder, Zhejiang Shouxian Valley Investment Management Co., Ltd., holds 28.76% of the shares, amounting to 56,711,239 shares[10] Other Financial Metrics - The weighted average return on equity for Q1 2023 was 3.23%, a decrease of 0.34 percentage points year-on-year[5] - The total current liabilities increased to CNY 531,550,902.54 from CNY 477,765,151.63, reflecting a growth of about 11.2%[15] - The company's long-term investments in equity increased slightly to CNY 5,988,270.17 from CNY 5,927,692.09, showing a growth of approximately 1.0%[14] - The non-current assets totaled CNY 1,015,937,901.80, up from CNY 994,178,202.27, indicating an increase of about 2.5%[15] - The company's accounts receivable decreased to CNY 88,648,652.43 from CNY 113,660,007.77, a decline of approximately 22.0%[14] - Research and development expenses for Q1 2023 were CNY 11,429,365.94, an increase of 5.68% from CNY 10,816,003.23 in Q1 2022[19] Prepayments - The company experienced a significant increase in prepayments, with a rise of 117.20% in advance payments received during the reporting period[8] - The company reported a significant increase in prepayments to CNY 15,193,252.07 from CNY 13,965,241.53, which is an increase of approximately 8.8%[14] Accounting Standards - The company did not apply new accounting standards or interpretations for the first time in 2023[25]

Financial Performance - The company's operating revenue for 2022 was approximately CNY 829.07 million, representing an increase of 8.07% compared to CNY 767.14 million in 2021[25]. - Net profit attributable to shareholders of the listed company reached approximately CNY 277.78 million, a significant increase of 38.32% from CNY 200.83 million in the previous year[25]. - The net profit after deducting non-recurring gains and losses was approximately CNY 253.18 million, up 27.39% from CNY 198.75 million in 2021[25]. - The company's total assets increased by 45.54% to approximately CNY 2.86 billion from CNY 1.96 billion in 2021[25]. - The weighted average return on net assets rose to 16.07%, an increase of 2.53 percentage points from 13.54% in the previous year[26]. - Basic earnings per share for 2022 were CNY 1.43, reflecting a 36.19% increase from CNY 1.05 in 2021[26]. - The cash flow from operating activities for 2022 was approximately CNY 341.28 million, an increase of 15.03% compared to CNY 296.70 million in 2021[25]. - The company's net assets attributable to shareholders reached approximately CNY 1.91 billion, up 17.65% from CNY 1.62 billion at the end of 2021[25]. Corporate Governance - The company has received a standard unqualified audit report from Lixin Certified Public Accountants[5]. - All board members attended the board meeting, ensuring the integrity of the annual report[11]. - The company confirms that there are no non-operating fund occupations by controlling shareholders or related parties[8]. - The company has not violated any decision-making procedures in providing guarantees[9]. - The board of directors consists of 9 members, including 3 independent directors, ensuring compliance with relevant laws and regulations[190]. - The supervisory board is composed of 3 members, maintaining independence and oversight of the company's operations and management[190]. - The company strictly adheres to regulations regarding related party transactions, ensuring fairness and compliance in pricing and decision-making processes[191]. - There were no instances of non-operating fund occupation by the controlling shareholder or its affiliates during the reporting period[191]. Market Expansion and Strategy - The company plans to continue expanding its market presence and invest in new product development to drive future growth[24]. - The company signed contracts with 14 new city agents, expanding its sales network across multiple regions including Kunming, Guiyang, and Wuhan[36]. - The company launched a new marketing strategy that includes high-speed train advertisements, enhancing brand visibility across 18 provinces and regions[36]. - The company plans to expand its market presence outside Zhejiang province and increase efforts in community promotion and recruiting distributors for spore powder tablets[109]. - The company is focusing on the development of high-quality traditional Chinese medicine varieties, including Lingzhi and Dendrobium, supported by a clinical efficacy database[166]. - The company is actively pursuing key technology upgrades and digital transformation projects to enhance operational efficiency and product quality[175]. - The company aims to implement a development strategy centered on innovation in biotechnology and the cultivation of rare medicinal materials[165]. Research and Development - The company has a research and development team of 145 people, including 46 with senior titles and 11 PhDs[53]. - Research and development expenses amounted to 47.82 million yuan, a decrease of 5.90% from the previous year[98]. - The company is focusing on improving technology processes, developing new strains, and enhancing production equipment as part of its R&D strategy[138]. - The company has several ongoing R&D projects, including traditional Chinese medicine formulations aimed at various health conditions[140]. - The company is developing a new product, "寿仙谷牌铁皮石斛饮料," aimed at enhancing immunity, which is currently in the registration process[141]. - The company has maintained a consistent R&D investment strategy over the past three years, with a slight decrease in the percentage of revenue allocated to R&D[139]. - The company has registered multiple new health food products, including "Shouxiangu Brand Iron Skin Dendrobium Drink" and "Shouxiangu Brand Monkey Head Mushroom Dendrobium Huangqi Tablets"[146]. Product Development and Innovation - The company’s proprietary processing technology for Ganoderma lucidum has been patented in seven countries, showcasing its innovation in product development[38]. - The company’s new product lines, including "Xianhu 1," "Xianhu 2," and "Xianhu 3," have received national variety protection, indicating successful innovation in product offerings[38]. - The company has developed a rare medicinal plant germplasm resource bank, collecting 117 Dendrobium germplasm resources and achieving high survival rates and yields through modern breeding techniques[86]. - The company’s "Xianhua 1", "Xianhua 2", and "Xianhua 3" Ganoderma varieties have been recognized for their strong resistance and high active ingredient content, contributing to its competitive advantage[84]. - The company is actively working on the safety evaluation and pharmacological research of its traditional Chinese medicine products[140]. Social Responsibility and Community Engagement - The company is actively involved in social responsibility initiatives, including donations of health products to frontline medical workers[57]. - The company has implemented a "common prosperity model" that integrates rental income, labor, cooperative product sales, and technology promotion, which has received high praise from government bodies[57]. - The company has been awarded multiple honors, including being named a national science popularization education base and a green factory in Zhejiang Province[58]. Financial Management and Investments - The company’s investment activities generated a net cash flow of -85.39 million yuan, a significant improvement from -233.72 million yuan in the previous year[98]. - Cash and cash equivalents rose by 124.89% to ¥1,524,712,390.54, mainly due to funds received from the issuance of convertible bonds[128]. - The company’s bonds payable surged by 371.00% to ¥412,589,185.71, resulting from the issuance of convertible bonds during the reporting period[130]. - The company has proposed a plan for the public issuance of convertible bonds, with a feasibility analysis conducted on the use of raised funds[194]. Human Resources and Management - The total pre-tax remuneration for executives during the reporting period amounted to 452.55 million yuan[197]. - The company has implemented a "Four Eagles" human resources action plan to strengthen performance assessment and talent acquisition, focusing on attracting passionate and creative young talent[177]. - The management team has experienced changes, with several executives leaving and new appointments made to strengthen leadership[198]. - The leadership team includes professionals with extensive experience in finance, administration, and research, which is expected to drive innovation[200]. Future Outlook - Future guidance indicates a positive outlook for revenue growth and market expansion in the coming years[198]. - The company aims for a revenue growth rate and net profit growth rate of over 20% year-on-year in 2023[170]. - The company is committed to improving shareholder value through effective management and strategic initiatives[198].